Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 305

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 305
---
 under the terms of the Framework Supply Agreement and, moreover, that the Company was never served with    
 German judicial documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the       
 applicable German and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company are       
 in the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable  
 German judgement could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s          
 purported ruling. A hearing to annul the judgement in Germany was scheduled for April 2025 and a hearing to discuss the enforcement     
 in Israel was scheduled for June 2025. With respect to the hearing to annul the judgment, the judge requested that the parties submit   
 their arguments in writing. The Company submitted its arguments to the German court by way of a brief on April 11, 2025. In May 2025,   
 the German court issued a judgment dismissing the Company’s annulment claim. On July 4, 2025, the Company entered into an agreement     
 with CSL pursuant to which the Company is required to make an immediate payment of $30 and an additional payment of $300, by the        
 Company to CSL subsequent to the closing of Company’s initial public offering, as well as reimburse certain of CSL’s legal              
 expenses and two future payments of $300 and $200 by the Company to CSL upon the achievement of certain global sales milestones.        
 As a result, in the second half of 2024, the Company recorded a provision of $430.                                                      |

The Company’s product has yet
to be approved by FDA and is still in clinical trials and in any event, is not using CSL’s fibrinogen.

<div align='center'>F-46</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

From time to time, the Company
has been and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively,
“Legal Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company
believes will have a material adverse impact on the business